Yang Liu1, Eleanor Carson-Walter2, Kevin A Walter3. 1. Department of Neurosurgery, University of Rochester School of Medicine and Dentistry, Rochester, NY, U.S.A. yang_liu@urmc.rochester.edu kevin_walter@urmc.rochester.edu. 2. Department of Neurosurgery, University of Rochester School of Medicine and Dentistry, Rochester, NY, U.S.A. 3. Department of Neurosurgery, University of Rochester School of Medicine and Dentistry, Rochester, NY, U.S.A. Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY, U.S.A. yang_liu@urmc.rochester.edu kevin_walter@urmc.rochester.edu.
Abstract
BACKGROUND: The functional contribution of chemokine receptor CXCR7 to malignant brain tumor biology remains controversial. MATERIALS AND METHODS: Complementary methods were used to confirm CXCR7 expression in clinical glioblastoma multiforme (GBM) specimens and multiple GBM cell lines. Loss-of-function studies were performed using small interfering RNA (siRNA) technology. RESULTS: Elevated CXCR7 levels correlated with reduced survival in glioma patients. CXCR7 was expressed by GBM cell lines and stem-like progenitor cells. Knockdown of CXCR7 by siRNA attenuated phosphorylation of the extracellular signal-regulated kinase (ERK1/2) signaling pathway in response to CXCL12 and resulted in significantly reduced cell proliferation, invasion and migration. Similarly, treatment of glioma cells with a small molecule antagonist of CXCR7, CCX771, significantly inhibited cell proliferation and invasion. CONCLUSION: CXCR7 actively promotes the proliferation and invasive behavior of glioma tumor cells and stem-like progenitor cells and may be a potential target for glioma therapy. Copyright
BACKGROUND: The functional contribution of chemokine receptor CXCR7 to malignant brain tumor biology remains controversial. MATERIALS AND METHODS: Complementary methods were used to confirm CXCR7 expression in clinical glioblastoma multiforme (GBM) specimens and multiple GBM cell lines. Loss-of-function studies were performed using small interfering RNA (siRNA) technology. RESULTS: Elevated CXCR7 levels correlated with reduced survival in gliomapatients. CXCR7 was expressed by GBM cell lines and stem-like progenitor cells. Knockdown of CXCR7 by siRNA attenuated phosphorylation of the extracellular signal-regulated kinase (ERK1/2) signaling pathway in response to CXCL12 and resulted in significantly reduced cell proliferation, invasion and migration. Similarly, treatment of glioma cells with a small molecule antagonist of CXCR7, CCX771, significantly inhibited cell proliferation and invasion. CONCLUSION:CXCR7 actively promotes the proliferation and invasive behavior of glioma tumor cells and stem-like progenitor cells and may be a potential target for glioma therapy. Copyright
Authors: Solbi Kim; Ji-Eun Kim; Nayoung Kim; Mina Joo; Myung-Won Lee; Heung Jin Jeon; Hyewon Ryu; Ik-Chan Song; Gyu-Yong Song; Hyo Jin Lee Journal: Am J Cancer Res Date: 2019-09-01 Impact factor: 6.166
Authors: Hong Xian Wang; Lin Yu Tao; K E Qi; Hao Yun Zhang; Duo Feng; Wen Jun Wei; Heng Kong; Tian Wen Chen; Qiu Sheng Lin; Dao Jin Chen Journal: Mol Clin Oncol Date: 2015-09-15
Authors: Giovanni Luca Gravina; Andrea Mancini; Francesco Marampon; Alessandro Colapietro; Simona Delle Monache; Roberta Sferra; Flora Vitale; Peter J Richardson; Lee Patient; Stephen Burbidge; Claudio Festuccia Journal: J Hematol Oncol Date: 2017-01-05 Impact factor: 17.388
Authors: Ido D Weiss; Lyn M Huff; Moses O Evbuomwan; Xin Xu; Hong Duc Dang; Daniel S Velez; Satya P Singh; Hongwei H Zhang; Paul J Gardina; Jae-Ho Lee; Liza Lindenberg; Timothy G Myers; Chang H Paik; David S Schrump; Stefania Pittaluga; Peter L Choyke; Tito Fojo; Joshua M Farber Journal: Oncotarget Date: 2017-08-04